American Century Companies Inc Immunovant, Inc. Transaction History

American Century Companies Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$15.27 - $19.72 $5,375 - $6,941	-352 Reduced 2.57%	13,352 $207,000
Q4 2022 Feb 13, 2023	BUY	$6.59 - $17.75 $90,309 - $243,246	13,704 New	13,704 $243,000
Q4 2021 Feb 07, 2022	SELL	$7.33 - $9.32 $1.84 Million - $2.34 Million	-250,854 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$7.01 - $11.37 $785 - $1,273	112 Added 0.04%	250,854 $2.18 Million
Q2 2021 Aug 05, 2021	BUY	$9.4 - $16.85 $13,451 - $24,112	1,431 Added 0.57%	250,742 $2.65 Million
Q1 2021 May 14, 2021	BUY	$13.08 - $49.6 $3.26 Million - $12.4 Million	249,311 New	249,311 $4 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

Stay updated on American Century Companies Inc with notifications on news.